These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 8961513)
1. Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response. Bishop SA; Stokes CR; Gruffydd-Jones TJ; Whiting CV; Humphries JE; Osborne R; Papanastasopoulou M; Harbour DA Vaccine; 1996 Sep; 14(13):1243-50. PubMed ID: 8961513 [TBL] [Abstract][Full Text] [Related]
2. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898 [TBL] [Abstract][Full Text] [Related]
3. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection. Aranyos AM; Roff SR; Pu R; Owen JL; Coleman JK; Yamamoto JK Vaccine; 2016 Mar; 34(12):1480-8. PubMed ID: 26802606 [TBL] [Abstract][Full Text] [Related]
4. Mechanism(s) of FIV vaccine protection. Pu R; Tellier MC; Yamamoto JK Leukemia; 1997 Apr; 11 Suppl 3():98-101. PubMed ID: 9209311 [TBL] [Abstract][Full Text] [Related]
5. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats. Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250 [TBL] [Abstract][Full Text] [Related]
6. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins. Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919 [TBL] [Abstract][Full Text] [Related]
7. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine. Sahay B; Aranyos AM; McAvoy A; Yamamoto JK Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186 [TBL] [Abstract][Full Text] [Related]
9. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Gardner MB Antiviral Res; 1991 May; 15(4):267-86. PubMed ID: 1659310 [TBL] [Abstract][Full Text] [Related]
10. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection. Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250 [TBL] [Abstract][Full Text] [Related]
11. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection. Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. Matteucci D; Poli A; Mazzetti P; Sozzi S; Bonci F; Isola P; Zaccaro L; Giannecchini S; Calandrella M; Pistello M; Specter S; Bendinelli M J Virol; 2000 Dec; 74(23):10911-9. PubMed ID: 11069985 [TBL] [Abstract][Full Text] [Related]
13. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311 [TBL] [Abstract][Full Text] [Related]
14. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. Giannecchini S; Isola P; Sichi O; Matteucci D; Pistello M; Zaccaro L; Del Mauro D; Bendinelli M J Virol; 2002 Jul; 76(14):6882-92. PubMed ID: 12072489 [TBL] [Abstract][Full Text] [Related]
15. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558 [TBL] [Abstract][Full Text] [Related]
16. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067 [TBL] [Abstract][Full Text] [Related]
17. Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats. Levy JK; Crawford PC; Kusuhara H; Motokawa K; Gemma T; Watanabe R; Arai S; Bienzle D; Hohdatsu T J Vet Intern Med; 2008; 22(2):330-4. PubMed ID: 18371028 [TBL] [Abstract][Full Text] [Related]
18. Enhancement after feline immunodeficiency virus vaccination. Hosie MJ; Osborne R; Reid G; Neil JC; Jarrett O Vet Immunol Immunopathol; 1992 Dec; 35(1-2):191-7. PubMed ID: 1337397 [TBL] [Abstract][Full Text] [Related]
19. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon. Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309 [TBL] [Abstract][Full Text] [Related]
20. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine. Stickney A; Ghosh S; Cave NJ; Dunowska M Vet Microbiol; 2020 Nov; 250():108865. PubMed ID: 33045631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]